Etalocib

Etalocib
Names
	Preferred IUPAC name 25-Ethyl-14-fluoro-22-hydroxy-82-propyl-3,7,9-trioxa-1,10(1),2(1,4),8(1,3)-tetrabenzenadecaphane-102-carboxylic acid
	Other names LY293111; VML 295
Identifiers
CAS Number	161172-51-6 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL329123 ;
ChemSpider	154905 ;
IUPHAR/BPS	2948;
KEGG	D04074 ;
PubChem CID	177941;
UNII	THY6RIW44R ;
CompTox Dashboard (EPA)	DTXSID70167073 ;
	InChI InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37) Key: YFIZRWPXUYFCSN-UHFFFAOYSA-N ;
	SMILES Fc1ccc(cc1)c4c(O)cc(OCCCOc3cccc(Oc2ccccc2C(=O)O)c3CCC)c(c4)CC;
Properties
Chemical formula	C33H33FO6
Molar mass	544.619 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	(what is ?)
	Infobox references

Etalocib is a drug candidate that was under development for the treatment of various types of cancer.^[1] It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist.^[2]

Clinical trials were conducted measuring efficacy for treatment of non-small cell lung cancer and pancreatic cancer and the inflammatory conditions asthma, psoriasis, and ulcerative colitis, but were suspended due to lack of efficacy.^[3]

References[]

^ Jänne, P. A.; Paz-Ares, L; Oh, Y; Eschbach, C; Hirsh, V; Enas, N; Brail, L; von Pawel, J (2014). "Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer". Journal of Thoracic Oncology. 9 (1): 126–31. doi:10.1097/JTO.0000000000000037. PMID 24346102.
^ Adrian, T. E.; Hennig, R; Friess, H; Ding, X (2008). "The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer". PPAR Research. 2008: 827096. doi:10.1155/2008/827096. PMC 2631651. PMID 19190780.
^ "Etalocib". Adisinsight. Retrieved 31 January 2017.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] Jänne, P. A.; Paz-Ares, L; Oh, Y; Eschbach, C; Hirsh, V; Enas, N; Brail, L; von Pawel, J (2014). "Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer". Journal of Thoracic Oncology. 9 (1): 126–31. doi:10.1097/JTO.0000000000000037. PMID 24346102.

[2] Adrian, T. E.; Hennig, R; Friess, H; Ding, X (2008). "The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer". PPAR Research. 2008: 827096. doi:10.1155/2008/827096. PMC 2631651. PMID 19190780.

[3] "Etalocib". Adisinsight. Retrieved 31 January 2017.

[1]

[2]

[3]

v t PPAR modulators
PPARα	Agonists: 15-HETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Clofibrate Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil Leukotriene B₄ Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone Antagonists: MK-886
PPARδ	Agonists: 15-HETE Arachidonic acid Bezafibrate Daidzein Elafibranor Genistein GW-0742 GW-501516 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists:
PPARγ	Agonists: 15-Deoxy-Δ^12,14-prostaglandin J₂ 15-HETE Aleglitazar Arachidonic acid Berberine Bezafibrate Cannabidiol Ciglitazone Daidzein Darglitazone Englitazone Etalocib Farglitazar Genistein Ibuprofen Indeglitazar Lobeglitazone Muraglitazar (muroglitazar) Netoglitazone Perfluorononanoic acid Pioglitazone Rivoglitazone Rosiglitazone Saroglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMs: BADGE EPI-001 Antagonists: Unknown:
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators

Names

Preferred IUPAC name 2⁵-Ethyl-1⁴-fluoro-2²-hydroxy-8²-propyl-3,7,9-trioxa-1,10(1),2(1,4),8(1,3)-tetrabenzenadecaphane-10²-carboxylic acid
Other names LY293111 VML 295
Identifiers
CAS Number	161172-51-6^N
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL329123^Y
ChemSpider	154905^Y
IUPHAR/BPS	2948
KEGG	D04074^Y
PubChem CID	177941
UNII	THY6RIW44R^Y
CompTox Dashboard (EPA)	DTXSID70167073
InChI InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)^Y Key: YFIZRWPXUYFCSN-UHFFFAOYSA-N^Y
SMILES Fc1ccc(cc1)c4c(O)cc(OCCCOc3cccc(Oc2ccccc2C(=O)O)c3CCC)c(c4)CC
Properties
Chemical formula	C₃₃H₃₃FO₆
Molar mass	544.619 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N (what is ^YN ?)
Infobox references